In a subsequent clinical trial for metastatic BCC, vismodegib treatment resulted in tumor regression; however, after three months, a novel SMO mutation was discovered in the tumor tissue and the treatment progress ceased [81,82]. This evidence concerns the gene SMO and skin basal cell carcinoma.